ReviewCurrent drug research reviews2026
Next-generation Mesoporous Silica Nanoparticles: Precision-engineered Platforms for Ovarian Cancer Therapy.
Review in Current drug research reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silica nanoparticles (SiNPs) with antifouling properties offer a promising approach for enhancing ovarian cancer (OC) therapy. OC remains one of the deadliest gynecological malignancies due to late-stage diagnosis, high recurrence rates, and limited treatment efficacy. Conventional therapies, such as chemotherapy, often face challenges due to drug resistance and limited targeting ability. The development of SiNPs with antifouling capabilities aims to address these issues by improving drug delivery efficiency, reducing non-specific interactions, and enhancing biocompatibility. Functionalizing SiNPs with cancer-specific ligands or antibodies can further improve targeting and uptake by ovarian cancer cells while reducing the impact on healthy tissues. Additionally, the porous structure of SiNPs allows for the loading of multiple therapeutic agents, enabling combination therapies that can overcome drug resistance mechanisms. In order to overcome these constraints and enhance MSN efficacy in cancer theranostics, this study aims to highlight technical advancements, including tumor-specific, stimuli-responsive "smart" MSNs and multimodal MSN- based hybrid nanoplatforms. This review provides thorough knowledge about the role of mesoporous silica nanoparticles for the treatment of ovarian cancer, highlighting important areas for further study as well as the difficulties associated with this area. To possibly improve therapeutic results by offering more accurate and targeted theranostic methods, we want to highlight the vitality of MSN technology as well as the significance of recent research and developments in this area. Overall, antifouling SiNPs represent a versatile and effective platform for ovarian cancer treatment, with the potential to improve therapeutic outcomes and reduce side effects.
Indexed as
Identifiers
40873364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.